| Autor: |
Nguyen Ho, Phuong Thuy, van Arendonk, Joyce, Steketee, Rebecca M. E., van Rooij, Frank J. A., Roshchupkin, Gennady V., Ikram, M. Arfan, Vernooij, Meike W., Neitzel, Julia |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2023, Vol. 19 Issue 12, p5506-5517, 12p |
| Abstrakt: |
INTRODUCTION: Reliable models to predict amyloid beta (Aβ) positivity in the general aging population are lacking but could become cost‐efficient tools to identify individuals at risk of developing Alzheimer's disease. METHODS: We developed Aβ prediction models in the clinical Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study (n = 4,119) including a broad range of easily ascertainable predictors (demographics, cognition and daily functioning, health and lifestyle factors). Importantly, we determined the generalizability of our models in the population‐based Rotterdam Study (n = 500). RESULTS: The best performing model in the A4 Study (area under the curve [AUC] = 0.73 [0.69–0.76]), including age, apolipoprotein E (APOE) ε4 genotype, family history of dementia, and subjective and objective measures of cognition, walking duration and sleep behavior, was validated in the independent Rotterdam Study with higher accuracy (AUC = 0.85 [0.81–0.89]). Yet, the improvement relative to a model including only age and APOE ε4 was marginal. DISCUSSION: Aβ prediction models including inexpensive and non‐invasive measures were successfully applied to a general population–derived sample more representative of typical older non‐demented adults. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
